Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
I am interested in...
Wayfinder menu
VIVO
Research Home
Departments
SPORE in Prostate Cancer
Explore this Website
I am interested in...
Wayfinder menu
VIVO
Research Home
Departments
Home
About Us
Toggle About Us menu options
Affiliations
Donate
Resources
Job Opportunities
Contact Us
Research
Toggle Research menu options
Project 1
Project 2
Project 3
Project 4
Programs
Toggle Programs menu options
Career Enhancement Program
Toggle Career Enhancement Program menu options
2023 CEP Projects
Developmental Research Program
Toggle Developmental Research Program menu options
2023 DRP Awardee Projects
Cores
Toggle Cores menu options
Administrative Core
Biospecimen & Pathology
Computational Biology - Biostatistics
Investigators
Publications
News
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Research
Programs
Cores
Investigators
Publications
News
Home
Publications
Publications
Found 53 results
Author
Title
Type
Year
Journal Article
Stopsack KH
,
Huang Y
,
Tyekucheva S
,
Gerke TA
,
Bango C
,
Elfandy H
,
Bowden M
,
Penney KL
,
Roberts TM
,
Parmigiani G
et al.
. 2020.
Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation.
.
Clin Cancer Res. 26(22):5903-5913.
Pisapia DJ
,
Salvatore S
,
Pauli C
,
Hissong E
,
Eng K
,
Prandi D
,
Sailer V-W
,
Robinson BD
,
Park K
,
Cyrta J
et al.
. 2017.
Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.
.
JCO Precis Oncol. 2017
Berger A
,
Brady NJ
,
Bareja R
,
Robinson B
,
Conteduca V
,
Augello MA
,
Puca L
,
Ahmed A
,
Dardenne E
,
Lu X
et al.
. 2019.
N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.
.
J Clin Invest. 129(9):3924-3940.
Aytes A
,
Giacobbe A
,
Mitrofanova A
,
Ruggero K
,
Cyrta J
,
Arriaga J
,
Palomero L
,
Farran-Matas S
,
Rubin MA
,
Shen MM
et al.
. 2018.
NSD2 is a conserved driver of metastatic prostate cancer progression.
.
Nat Commun. 9(1):5201.
Guo H
,
Ci X
,
Ahmed M
,
Hua JTony
,
Soares F
,
Lin D
,
Puca L
,
Vosoughi A
,
Xue H
,
Li E
et al.
. 2019.
ONECUT2 is a driver of neuroendocrine prostate cancer.
.
Nat Commun. 10(1):278.
Puca L
,
Bareja R
,
Prandi D
,
Shaw R
,
Benelli M
,
Karthaus WR
,
Hess J
,
Sigouros M
,
Donoghue A
,
Kossai M
et al.
. 2018.
Patient derived organoids to model rare prostate cancer phenotypes.
.
Nat Commun. 9(1):2404.
Park K
,
Rubin MA
,
Sboner A
,
Mosquera JMiguel
,
Elemento O
,
Tran H
,
Eng KW
,
Ramazanoglu S
,
Rolon RMMarrero
,
Scognamiglio T
et al.
. 2020.
Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome.
.
Arch Pathol Lab Med. 144(12):1535-1546.
Beltran H
,
Oromendia C
,
Danila DC
,
Montgomery B
,
Hoimes C
,
Szmulewitz RZ
,
Vaishampayan U
,
Armstrong AJ
,
Stein M
,
Pinski J
et al.
. 2018.
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.
.
Clin Cancer Res.
Nowak DG
,
Katsenelson KCohen
,
Watrud KE
,
Chen M
,
Mathew G
,
D'Andrea VD
,
Lee MF
,
Swamynathan MMosur
,
Casanova-Salas I
,
Jibilian MC
et al.
. 2019.
The PHLPP2 phosphatase is a druggable driver of prostate cancer progression.
.
J Cell Biol. 218(6):1943-1957.
Boehm KMichael
,
Bhinder B
,
Raja VJoseph
,
Dephoure N
,
Elemento O
. 2019.
Predicting peptide presentation by major histocompatibility complex class I: an improved machine learning approach to the immunopeptidome.
.
BMC Bioinformatics. 20(1):7.
Triscott J
,
Rubin MA
. 2018.
Prostate Power Play: Does Pik3ca Accelerate Pten-Deficient Cancer Progression?
Cancer Discov. 8(6):682-685.
Li JJ
,
Shen MM
. 2019.
Prostate Stem Cells and Cancer Stem Cells.
.
Cold Spring Harb Perspect Med. 9(6)
Grbesa I
,
Augello MA
,
Liu D
,
McNally DR
,
Gaffney CD
,
Huang D
,
Lin K
,
Ivenitsky D
,
Goueli R
,
Robinson BD
et al.
. 2021.
Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity.
.
Cell Rep. 36(10):109625.
Choudhury AD
,
Beltran H
. 2019.
Retinoblastoma Loss in Cancer: Casting a Wider Net.
.
Clin Cancer Res. 25(14):4199-4201.
Rubin MA
,
Beltran H
,
Ballman KV
,
Sboner A
,
Cyrta J
,
Demichelis F
,
Augspach A
,
De Filippo MRosaria
,
Prandi D
,
Thienger P
et al.
. 2020.
Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity.
.
Nat Commun. 11(1):5549.
Ricker E
,
Verma A
,
Marullo R
,
Gupta S
,
Ye C
,
Pannellini T
,
Manni M
,
Tam W
,
Inghirami G
,
Elemento O
et al.
. 2020.
Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma.
.
Sci Rep. 10(1):13094.
Thienger P
,
Rubin MA
. 2020.
SETting Up for Epigenetic Regulation of Advanced Prostate Cancer.
.
Cancer Cell. 38(3):309-311.
Robinson BD
,
Shen MM
,
Crowley L
,
Cambuli F
,
Aparicio L
,
Shibata M
,
Xuan S
,
Loda M
,
Li W
,
Hibshoosh H
et al.
. 2020.
A single-cell atlas of the mouse and human prostate reveals heterogeneity and conservation of epithelial progenitors.
.
Elife. 9
Lehmann GL
,
Hanke-Gogokhia C
,
Hu Y
,
Bareja R
,
Salfati Z
,
Ginsberg M
,
Nolan DJ
,
Mendez-Huergo SP
,
Dalotto-Moreno T
,
Wojcinski A
et al.
. 2020.
Single-cell profiling reveals an endothelium-mediated immunomodulatory pathway in the eye choroid.
.
J Exp Med. 217(6)
Conteduca V
,
Beltran H
,
Nanus DM
,
Tagawa ST
,
Mosquera JMiguel
,
Sboner A
,
Elemento O
,
Ku S-Y
,
Puca L
,
Slade M
et al.
. 2020.
SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.
.
Mol Cancer Ther. 19(5):1157-1164.
Shoag J
,
Liu D
,
Blattner M
,
Sboner A
,
Park K
,
Deonarine L
,
Robinson BD
,
Mosquera JMiguel
,
Chen Y
,
Rubin MA
et al.
. 2018.
SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.
.
J Clin Invest. 128(1):381-386.
Gjyrezi A
,
Xie F
,
Voznesensky O
,
Khanna P
,
Calagua C
,
Bai Y
,
Kung J
,
Wu J
,
Corey E
,
Montgomery B
et al.
. 2020.
Taxane resistance in prostate cancer is mediated by decreased drug-target engagement.
.
J Clin Invest. 130(6):3287-3298.
Brady NJ
,
Bagadion AM
,
Singh R
,
Conteduca V
,
Van Emmenis L
,
Arceci E
,
Pakula H
,
Carelli R
,
Khani F
,
Bakht M
et al.
. 2021.
Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.
.
Nat Commun. 12(1):3372.
Beltran H
,
Demichelis F
. 2021.
Therapy considerations in neuroendocrine prostate cancer: what next?
Endocr Relat Cancer. 28(8):T67-T78.
Locallo A
,
Prandi D
,
Fedrizzi T
,
Demichelis F
. 2019.
TPES: tumor purity estimation from SNVs.
.
Bioinformatics. 35(21):4433-4435.
« first
‹ previous
1
2
(current)
3
next ›
last »